looking for a cure
Cureveda is focused on the discovery, development and commercialization of novel small molecule drugs for the treatment of inflammatory, autoimmune and neurological diseases.
Cureveda has identified compounds that activate the Nrf2 transcription factor, stimulating downstream antioxidant pathways that protect cells by suppressing inflammation and oxidative stress. This program is based on technology developed by Dr. Shyam Biswal and colleagues at Johns Hopkins University and licensed to Cureveda. The Company's Nrf2 activation technology platform offers potential treatments for a wide range of diseases where there is an unmet need for more effective therapies, including Chronic Obstructive Pulmonary Disease (COPD), Scleroderma, Ulcerative Colitis and Multiple Sclerosis. Cureveda's approach targets the underlying disease process, rather than just improving symptoms as is the case with most current therapies.